Literature DB >> 24265277

Benefits of vascular normalization are dose and time dependent--letter.

Yuhui Huang1, Triantafyllos Stylianopoulos, Dan G Duda, Dai Fukumura, Rakesh K Jain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24265277      PMCID： PMC3876035          DOI： 10.1158/0008-5472.CAN-13-1989

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  5 in total

1.  Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Authors:  Cinthia V Pastuskovas; Eduardo E Mundo; Simon P Williams; Tapan K Nayak; Jason Ho; Sheila Ulufatu; Suzanna Clark; Sarajane Ross; Eric Cheng; Kathryn Parsons-Reponte; Gary Cain; Marjie Van Hoy; Nicholas Majidy; Sheila Bheddah; Josefa dela Cruz Chuh; Katherine R Kozak; Nicholas Lewin-Koh; Peter Nauka; Daniela Bumbaca; Mark Sliwkowski; Jay Tibbitts; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; C Andrew Boswell
Journal:  Mol Cancer Ther       Date:  2012-01-05       Impact factor: 6.261

2.  Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Authors:  Marlous Arjaans; Thijs H Oude Munnink; Sjoukje F Oosting; Anton G T Terwisscha van Scheltinga; Jourik A Gietema; Erik T Garbacik; Hetty Timmer-Bosscha; Marjolijn N Lub-de Hooge; Carolina P Schröder; Elisabeth G E de Vries
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

3.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Authors:  Yuhui Huang; Jianping Yuan; Elda Righi; Walid S Kamoun; Marek Ancukiewicz; Jean Nezivar; Michael Santosuosso; John D Martin; Margaret R Martin; Fabrizio Vianello; Pierre Leblanc; Lance L Munn; Peigen Huang; Dan G Duda; Dai Fukumura; Rakesh K Jain; Mark C Poznansky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

Review 4.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

5.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner.

Authors:  Vikash P Chauhan; Triantafyllos Stylianopoulos; John D Martin; Zoran Popović; Ou Chen; Walid S Kamoun; Moungi G Bawendi; Dai Fukumura; Rakesh K Jain
Journal:  Nat Nanotechnol       Date:  2012-04-08       Impact factor: 39.213
  5 in total
  36 in total

1.  Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.

Authors:  Jia-Yu Liu; Tsaiyu Chiang; Chun-Hung Liu; Guann-Gen Chern; Ts-Ting Lin; Dong-Yu Gao; Yunching Chen
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

Review 2.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

Review 3.  VEGF in Signaling and Disease: Beyond Discovery and Development.

Authors:  Rajendra S Apte; Daniel S Chen; Napoleone Ferrara
Journal:  Cell       Date:  2019-03-07       Impact factor: 41.582

4.  3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.

Authors:  Huaming Yan; Mónica Romero-López; Lesly I Benitez; Kaijun Di; Hermann B Frieboes; Christopher C W Hughes; Daniela A Bota; John S Lowengrub
Journal:  Cancer Res       Date:  2017-05-23       Impact factor: 12.701

5.  Role of Autophagy in HIV-1 Matrix Protein p17-Driven Lymphangiogenesis.

Authors:  Pietro Mazzuca; Stefania Marsico; Kai Schulze; Stefania Mitola; Marina C Pils; Cinzia Giagulli; Carlos A Guzman; Arnaldo Caruso; Francesca Caccuri
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.

Authors:  Xichen Zheng; Zhaoxu Fang; Xiaomei Liu; Shengming Deng; Pei Zhou; Xuexiang Wang; Chenglin Zhang; Rongping Yin; Haitian Hu; Xiaolan Chen; Yijie Han; Yun Zhao; Steven H Lin; Songbing Qin; Xiaohua Wang; Betty Ys Kim; Penghui Zhou; Wen Jiang; Qingyu Wu; Yuhui Huang
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

7.  Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Authors:  Eleanor I Ager; Sergey V Kozin; Nathaniel D Kirkpatrick; Giorgio Seano; David P Kodack; Vasileios Askoxylakis; Yuhui Huang; Shom Goel; Matija Snuderl; Alona Muzikansky; Dianne M Finkelstein; Daniel T Dransfield; Laetitia Devy; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2015-02-20       Impact factor: 13.506

Review 8.  Strategies for improving drug delivery: nanocarriers and microenvironmental priming.

Authors:  Ayesha Khalid; Stefano Persano; Haifa Shen; Yuliang Zhao; Elvin Blanco; Mauro Ferrari; Joy Wolfram
Journal:  Expert Opin Drug Deliv       Date:  2016-10-11       Impact factor: 6.648

Review 9.  Improving immune-vascular crosstalk for cancer immunotherapy.

Authors:  Yuhui Huang; Betty Y S Kim; Charles K Chan; Stephen M Hahn; Irving L Weissman; Wen Jiang
Journal:  Nat Rev Immunol       Date:  2018-01-15       Impact factor: 53.106

10.  Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.

Authors:  Marco C Pinho; Pavlina Polaskova; Jayashree Kalpathy-Cramer; Dominique Jennings; Kyrre E Emblem; Rakesh K Jain; Bruce R Rosen; Patrick Y Wen; A Gregory Sorensen; Tracy T Batchelor; Elizabeth R Gerstner
Journal:  Oncologist       Date:  2013-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.